Valeant Pharmaceuticals ($VRX) may get some help in buying Cephalon ($CEPH) from one of that company's investors. A Pennsylvania pension fund has sued Cephalon, saying management has simply refused to consider Valeant's $5.7 billion buyout offer. And that, the pension fund alleges, shows the company is ignoring the best interests of the shareholders. Report